B3GALT6

Across TCGA pan-cancer cohorts, B3GALT6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated B3GALT6 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher B3GALT6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated B3GALT6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, UCEC, and LSCC are the cancer types where B3GALT6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.277	0.555	.001	38	view →
UCEC	DFS	Median	All	1.000	0.927	.021	14	view →
LSCC	DFS	Median	All	0.881	0.974	.003	8	view →
LUAD	DFS	Tertile	All	0.518	0.911	.018	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

B3GALT6–PDAC (DFS)

Open the PDAC breakdown →